Signia Integrated Xperience Hearing Aid Platform Named a Winner of the 2024 BIG Innovation Awards

Signia Integrated Xperience (IX)

Hearing aid innovator Signia has been named a winner of the 2024 BIG Innovation Awards for its Signia Integrated Xperience (IX) hearing aid platform, which provides unprecedented sound clarity and definition for wearers in noisy group conversations – even when the wearer or speakers are in motion. The recognition underscores the company’s commitment to delivering groundbreaking solutions to all hearing aid wearers that optimize hearing capabilities in even the most challenging listening scenarios.

BIG Innovation Awards

The BIG Innovation Awards recognize organizations and products that deliver premium innovation across verticals, bringing new ideas to life that will improve the lives of users and businesses. The new Signia Integrated Xperience hearing aid platform was recognized in the Healthcare category. Past BIG Innovation Award winners include Citi Ventures, Walgreens Boots Alliance, Velcro®, Bloomfire, and Colgate-Palmolive.

“The Signia Integrated Xperience platform is truly revolutionary in its ability to deliver maximum value and unparalleled hearing capabilities to all wearers, and it’s an honor to see that innovation recognized by such a prestigious award program,” said Mike O’Neil, President of Signia U.S. “Developing advanced hearing technology to best support hearing care professionals and their patients is at the core of Signia’s mission, and the Integrated Xperience platform does just that by pushing the boundaries of what hearing technology can do.”

As the world’s first hearing aid platform capable of pinpointing multiple conversation partners in real-time, Signia’s Integrated Xperience leverages insights into the changing positions of speakers to ensure uninterrupted engagement in even the most noisy, immersive environments.

Signia’s RealTime Conversation Enhancement

Integrated Xperience features Signia’s RealTime Conversation Enhancement solution that analyzes, augments, and adapts to the dynamic flow of multi-party conversation environments. The technology works in three stages, allowing wearers to engage, interact, and participate in noisy group conversations regardless of location, movement, and noise level.

The Integrated Xperience platform is currently available in Signia’s Pure Charge&Go IX and Silk Charge&Go IX hearing aid models, offering a substantial improvement in conversational ability for patients.

“The hearing aids built on Signia’s Integrated Xperience platform ultimately allow wearers to enjoy more meaningful lives with richer conversations,” said Nicholas Hort, Vice President of Marketing for Signia U.S. “With Integrated Xperience, we’ve set a new industry standard for hearing aid technology, prioritizing socialization, engagement, and a level of hearing ability that was previously unattainable in noisy, busy scenarios.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version